BioPharm International Emphasizes Standardization and Automation for Overcoming Complex Cell & Gene Therapy Manufacturing Challenges

June 20, 2026

BioPharm International USA

Overview

BioPharm International highlighted that standardization and automation are critical for navigating the complex landscape of cell and gene therapy (CGT) manufacturing. To improve global patient access to CGT, more consistent, reproducible, and cost-effective manufacturing processes are required. These enhancements are essential to reduce variability and improve process control, ultimately accelerating the commercialization and broad adoption of therapies. Supply chain challenges are also noted as a key area requiring solutions.

In Depth

Key Findings

BioPharm International concluded that strengthening process standardization and automation is imperative to overcome the complex challenges faced by cell and gene therapy (CGT) product manufacturing. This represents a crucial step towards realizing a future where CGTs can reach more patients in a more cost-effective manner.

Technical / Clinical Details

Manufacturing Consistency and Reproducibility: CGT products inherently face challenges with batch-to-batch quality variability. By implementing standardized protocols and automated manufacturing systems, process variability can be minimized, significantly improving product consistency and reproducibility.
Improved Cost-Effectiveness: Current CGT manufacturing is heavily manual and costly, posing a significant barrier to widespread adoption. Automation can substantially reduce manufacturing costs by decreasing labor expenses and increasing throughput, thereby making therapies more affordable.
Enhanced Process Control: Real-time monitoring and automated control systems enable stringent management of Critical Process Parameters (CPPs), allowing for rapid detection and correction of process deviations. This reduces the risk of batch failures and ensures product safety and quality.
Simplified Technology Transfer: Standardized, modular manufacturing platforms simplify the technology transfer process from research and development to commercial production. This shortens development timelines and accelerates the market entry of new products.
Supply Chain Challenges: CGT products often require strict temperature control and rapid transportation. Digitalization and integration of the supply chain are essential to address these challenges and ensure product integrity from manufacturing to patient delivery.

Background & Context

Cell and gene therapies are expanding treatment options for a wide range of severe diseases, but the complexity of their manufacturing processes and associated high costs remain the biggest impediments to global patient access. The industry is seeking sustainable manufacturing models to overcome these barriers and enable CGT products to become mainstream therapies. Standardization and automation are considered the technical and strategic cornerstones for achieving this goal.

Strategic Significance & Outlook

Advancements in standardization and automation in CGT manufacturing will significantly improve manufacturing efficiency and product quality, contributing to reduced therapy costs. This will enable more patients to benefit from these innovative treatments. In the future, the integration of AI and machine learning is expected to further optimize and predict manufacturing processes. This movement will support the sustainable growth of the cell and gene therapy market and serve as a crucial element in shaping the future of medicine.

Source: https://www.bioprocessintl.com/cell-therapies/navigating-the-complex-landscape-of-cell-and-gene-therapy-manufacturing

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.